Roche gets Phase 3 trial waiver for higher dose of multiple sclerosis drug

1777282629 6654



CDSCO expert panel grants waiver for 920 mg Ocrelizumab, subject to Roche conducting a Phase 4 clinical trial in the Indian population for proposed indications



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *